AngioDynamics, Inc. (ANGO) EPS Estimated At $0.20

AngioDynamics, Inc. (NASDAQ:ANGO) LogoInvestors sentiment increased to 1.5 in Q2 2018. Its up 0.04, from 1.46 in 2018Q1. It improved, as 10 investors sold AngioDynamics, Inc. shares while 44 reduced holdings. 29 funds opened positions while 52 raised stakes. 35.30 million shares or 1.16% more from 34.89 million shares in 2018Q1 were reported.
Systematic Fincl Ltd Partnership has 82,135 shares for 0.04% of their portfolio. Regions Financial has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). California State Teachers Retirement reported 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Vanguard Gru has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Serv Automobile Association holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 4,284 shares. Heartland stated it has 0.52% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Rothschild Asset Mngmt Incorporated has 0.02% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Macquarie Grp Limited, a Australia-based fund reported 15,500 shares. Ameritas Invest Prns has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Clarivest Asset Mgmt Ltd Liability invested in 59,258 shares. Amer Group stated it has 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Goldman Sachs Gru Inc owns 109,143 shares for 0% of their portfolio. Granahan Invest Ma has invested 0.63% in AngioDynamics, Inc. (NASDAQ:ANGO). Mutual Of America Cap Mngmt Ltd Liability Company holds 0% or 135 shares in its portfolio. Invesco Limited has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO).

Since November 7, 2018, it had 0 buys, and 1 sale for $41,747 activity.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.20 EPS on January, 3.They anticipate $0.04 EPS change or 25.00 % from last quarter’s $0.16 EPS. ANGO’s profit would be $7.42M giving it 26.16 P/E if the $0.20 EPS is correct. After having $0.16 EPS previously, AngioDynamics, Inc.’s analysts see 25.00 % EPS growth. The stock increased 1.06% or $0.22 during the last trading session, reaching $20.93. About 309,496 shares traded or 54.37% up from the average. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 30.51% since December 7, 2017 and is uptrending. It has outperformed by 14.89% the S&P500.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $776.96 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 48.9 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More notable recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: Seekingalpha.com which released: “AngioDynamics, Inc. 2018 Q4 – Results – Earnings Call Slides – Seeking Alpha” on July 11, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma’s Q4 Miss, Sage Inks Deal With Japan’s Shionogi – Benzinga” published on June 14, 2018, Seekingalpha.com published: “AngioDynamics Slowly Building Confidence In Its Turnaround – Seeking Alpha” on July 12, 2018. More interesting news about AngioDynamics, Inc. (NASDAQ:ANGO) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading – Benzinga” published on June 27, 2018 as well as Nasdaq.com‘s news article titled: “AngioDynamics’ (ANGO) BioSentry Buyout to Boost Oncology – Nasdaq” with publication date: August 16, 2018.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.